Hyman Charles D Novartis Ag Transaction History

Hyman Charles D

$1.79 Billion
Q2 2024

A detailed history of Hyman Charles D transactions in Novartis Ag stock. As of the latest transaction made, Hyman Charles D holds 3,548 shares of NVS stock, worth $344,439. This represents 0.02% of its overall portfolio holdings.

Number of Shares

3,548

Previous 3,555 0.2%

Holding current value

$344,439

Previous $343,000 9.91%

% of portfolio

0.02%

Previous 0.02%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$92.57 - $107.37 $647 - $751	-7 Reduced 0.2%	3,548 $377,000
Q4 2023 Feb 06, 2024	BUY	$92.27 - $101.54 $4,798 - $5,280	52 Added 1.48%	3,555 $358,000
Q3 2023 Nov 01, 2023	BUY	$94.73 - $105.13 $7,483 - $8,305	79 Added 2.31%	3,503 $356,000
Q1 2023 May 04, 2023	BUY	$80.03 - $92.81 $3,441 - $3,990	43 Added 1.27%	3,424 $315,000
Q4 2022 Feb 06, 2023	BUY	$75.55 - $92.52 $528 - $647	7 Added 0.21%	3,381 $306,000
Q1 2021 Apr 28, 2021	SELL	$83.5 - $98.47 $2,922 - $3,446	-35 Reduced 1.03%	3,374 $288,000
Q4 2020 Feb 08, 2021	BUY	$78.07 - $94.43 $2,732 - $3,305	35 Added 1.04%	3,409 $322,000
Q3 2020 Oct 26, 2020	SELL	$82.14 - $91.0 $2,464 - $2,730	-30 Reduced 0.88%	3,374 $293,000
Q2 2020 Aug 06, 2020	SELL	$80.93 - $91.1 $25,897 - $29,152	-320 Reduced 8.59%	3,404 $297,000
Q1 2020 Apr 30, 2020	BUY	$70.67 - $99.01 $19,434 - $27,227	275 Added 7.97%	3,724 $307,000
Q2 2019 Jul 24, 2019	BUY	$75.4 - $92.8 $35,061 - $43,152	465 Added 15.58%	3,449 $315,000
Q4 2018 Jan 31, 2019	SELL	$73.66 - $82.02 $2,209 - $2,460	-30 Reduced 1.0%	2,984 $256,000
Q1 2018 May 07, 2018	SELL	$70.39 - $84.15 $9,221 - $11,023	-131 Reduced 4.17%	3,014 $244,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,145	3,145 $263,000

Others Institutions Holding NVS

# of Institutions

1,437

Shares Held

131M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $209B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hyman Charles D, based on Form 13F filings with the SEC.

News

Stay updated on Hyman Charles D with notifications on news.

Account